1081117 Agomelatine, anhedonia and underlying mechanisms(決定版）

索引

00:00 1.
Agomelatine, Anhedonia and Underlying Mechanism
00:05 2.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
00:06 3.
Positive mental health outcomes (eg, well-being) Biology of positive psychiatry constructs
00:07 4.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
00:09 5.
Agomelatine, Anhedonia and Underlying Mechanism
01:18 6.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
01:18 7.
Agomelatine, Anhedonia and Underlying Mechanism
02:09 8.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
02:24 9.
Agomelatine, Anhedonia and Underlying Mechanism
05:08 10.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
06:02 11.
Positive mental health outcomes (eg, well-being) Biology of positive psychiatry constructs
07:50 12.
Part I. Positive mental health outcomes —Agomelatine and anhedonia of MDD Part II. Biology of positive psychiatry constructs
08:10 13.
Aiming for Functional Recovery of MDD:Reasons to consider Agomelatine
10:26 14.
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open‐label, real‐world study
11:22 15.
Prevalence: apathy/ indifference/ low motivation— 20-40%Delayed or insidious onset Completely resolvable with a dose-lowering and/or discontinuation of the SSRI *180% of patients with SSRI-induced sexual dysfunction also describe clinically significant bl
12:27 16.
An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness.
13:06 17.
persistence of psychosocial dysfunction despite a symptomatic response to antidepressant treatment
13:43 18.
Slide 10
14:32 19.
Outline
15:01 20.
Building a neuroscience of pleasure and well-being (Happiness) *1
18:34 21.
PFC-Limbic-Midbrain
20:07 22.
Activating positive memory engrams suppresses depression-like behavior and anhedonia *1
21:46 23.
Outline
22:04 24.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:23 25.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
23:25 26.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:26 27.
Outline
23:31 28.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:32 29.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
24:29 30.
Agomelatine: effects on self-referential processing in the amygdala
24:45 31.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
27:48 32.
③ 7 days
27:48 33.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
28:03 34.
③ 7 days
29:01 35.
Towards a glutamate hypothesis of depression *1
32:11 36.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
32:12 37.
Towards a glutamate hypothesis of depression *1
32:32 38.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
32:54 39.
Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.
33:32 40.
The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders
36:30 41.
Chronic agomelatine treatment completely prevented the stress-induced increase of glutamate release in the rat prefrontal and frontal cortex.
37:46 42.
Hypothesis: Hippocampus is a critical structure for the generation of joy and happiness. *5
41:02 43.
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
42:52 44.
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
44:11 45.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
44:54 46.
Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
46:56 47.
Lateral Habenula
49:18 48.
各自的斷崖/ 守護的意義
51:37 49.
Outline
51:42 50.
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
52:27 51.
The effect of melatonin on glutamate- and its subtype agonists- induced ion currents in rat hippocampal CA1 neurons.
52:35 52.
Administration of UCM765(MT2 agonist) at a dose of 40 mg/kg promotes sleep, whereas a lower dose (10 mg/kg) reduces anxiety. These similar pharmacological effects occurring after the activation of the GABAergic and the MLT systems are likely due to the mu
52:48 53.
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin
53:43 54.
Melatonin in Antinociception: Its Therapeutic Applications
54:16 55.
Outline
54:19 56.
Hippocampal Substructural Vulnerability to Sleep Disturbance and Cognitive Impairment in Patients with Chronic Primary Insomnia: Magnetic Resonance Imaging Morphometry
55:12 57.
The Role of Sleep in Emotional Brain Function
55:44 58.
Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings
55:57 59.
Agomelatine increases and regulates slow-wave sleep.
56:19 60.
Conclusions(1)
57:25 61.
Conclusions(2)
58:06 62.
Slide 46
59:43 63.
Conclusions(2)
59:44 64.
Conclusions(1)
59:44 65.
Agomelatine increases and regulates slow-wave sleep.
59:45 66.
Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings
59:45 67.
The Role of Sleep in Emotional Brain Function
59:45 68.
Hippocampal Substructural Vulnerability to Sleep Disturbance and Cognitive Impairment in Patients with Chronic Primary Insomnia: Magnetic Resonance Imaging Morphometry
59:45 69.
Outline
59:46 70.
Melatonin in Antinociception: Its Therapeutic Applications
59:46 71.
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin
59:46 72.
Administration of UCM765(MT2 agonist) at a dose of 40 mg/kg promotes sleep, whereas a lower dose (10 mg/kg) reduces anxiety. These similar pharmacological effects occurring after the activation of the GABAergic and the MLT systems are likely due to the mu
59:47 73.
The effect of melatonin on glutamate- and its subtype agonists- induced ion currents in rat hippocampal CA1 neurons.
59:48 74.
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
59:48 75.
Outline
59:48 76.
各自的斷崖/ 守護的意義
59:48 77.
Lateral Habenula
59:49 78.
Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
59:49 79.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
59:50 80.
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
59:50 81.
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
59:51 82.
Hypothesis: Hippocampus is a critical structure for the generation of joy and happiness. *5
59:51 83.
Chronic agomelatine treatment completely prevented the stress-induced increase of glutamate release in the rat prefrontal and frontal cortex.
59:51 84.
The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders
59:52 85.
Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.
59:52 86.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
59:52 87.
Towards a glutamate hypothesis of depression *1
59:53 88.
③ 7 days
59:53 89.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
59:54 90.
Agomelatine: effects on self-referential processing in the amygdala
59:54 91.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
59:54 92.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
59:55 93.
Outline
59:55 94.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
1:01:26 95.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
1:01:26 96.
Agomelatine: effects on self-referential processing in the amygdala
1:01:27 97.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
1:01:29 98.
Agomelatine: effects on self-referential processing in the amygdala
1:01:29 99.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.

筆記 (0)

未登入或權限不足!

討論

講者：郭約瑟

日期：2019-11-17

觀看: 1002

00:00 1.
Agomelatine, Anhedonia and Underlying Mechanism
00:05 2.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
00:06 3.
Positive mental health outcomes (eg, well-being) Biology of positive psychiatry constructs
00:07 4.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
00:09 5.
Agomelatine, Anhedonia and Underlying Mechanism
01:18 6.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
01:18 7.
Agomelatine, Anhedonia and Underlying Mechanism
02:09 8.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
02:24 9.
Agomelatine, Anhedonia and Underlying Mechanism
05:08 10.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
06:02 11.
Positive mental health outcomes (eg, well-being) Biology of positive psychiatry constructs
07:50 12.
Part I. Positive mental health outcomes —Agomelatine and anhedonia of MDD Part II. Biology of positive psychiatry constructs
08:10 13.
Aiming for Functional Recovery of MDD:Reasons to consider Agomelatine
10:26 14.
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open‐label, real‐world study
11:22 15.
Prevalence: apathy/ indifference/ low motivation— 20-40%Delayed or insidious onset Completely resolvable with a dose-lowering and/or discontinuation of the SSRI *180% of patients with SSRI-induced sexual dysfunction also describe clinically significant bl
12:27 16.
An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness.
13:06 17.
persistence of psychosocial dysfunction despite a symptomatic response to antidepressant treatment
13:43 18.
Slide 10
14:32 19.
Outline
15:01 20.
Building a neuroscience of pleasure and well-being (Happiness) *1
18:34 21.
PFC-Limbic-Midbrain
20:07 22.
Activating positive memory engrams suppresses depression-like behavior and anhedonia *1
21:46 23.
Outline
22:04 24.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:23 25.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
23:25 26.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:26 27.
Outline
23:31 28.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:32 29.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
24:29 30.
Agomelatine: effects on self-referential processing in the amygdala
24:45 31.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
27:48 32.
③ 7 days
27:48 33.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
28:03 34.
③ 7 days
29:01 35.
Towards a glutamate hypothesis of depression *1
32:11 36.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
32:12 37.
Towards a glutamate hypothesis of depression *1
32:32 38.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
32:54 39.
Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.
33:32 40.
The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders
36:30 41.
Chronic agomelatine treatment completely prevented the stress-induced increase of glutamate release in the rat prefrontal and frontal cortex.
37:46 42.
Hypothesis: Hippocampus is a critical structure for the generation of joy and happiness. *5
41:02 43.
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
42:52 44.
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
44:11 45.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
44:54 46.
Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
46:56 47.
Lateral Habenula
49:18 48.
各自的斷崖/ 守護的意義
51:37 49.
Outline
51:42 50.
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
52:27 51.
The effect of melatonin on glutamate- and its subtype agonists- induced ion currents in rat hippocampal CA1 neurons.
52:35 52.
Administration of UCM765(MT2 agonist) at a dose of 40 mg/kg promotes sleep, whereas a lower dose (10 mg/kg) reduces anxiety. These similar pharmacological effects occurring after the activation of the GABAergic and the MLT systems are likely due to the mu
52:48 53.
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin
53:43 54.
Melatonin in Antinociception: Its Therapeutic Applications
54:16 55.
Outline
54:19 56.
Hippocampal Substructural Vulnerability to Sleep Disturbance and Cognitive Impairment in Patients with Chronic Primary Insomnia: Magnetic Resonance Imaging Morphometry
55:12 57.
The Role of Sleep in Emotional Brain Function
55:44 58.
Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings
55:57 59.
Agomelatine increases and regulates slow-wave sleep.
56:19 60.
Conclusions(1)
57:25 61.
Conclusions(2)
58:06 62.
Slide 46
59:43 63.
Conclusions(2)
59:44 64.
Conclusions(1)
59:44 65.
Agomelatine increases and regulates slow-wave sleep.
59:45 66.
Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings
59:45 67.
The Role of Sleep in Emotional Brain Function
59:45 68.
Hippocampal Substructural Vulnerability to Sleep Disturbance and Cognitive Impairment in Patients with Chronic Primary Insomnia: Magnetic Resonance Imaging Morphometry
59:45 69.
Outline
59:46 70.
Melatonin in Antinociception: Its Therapeutic Applications
59:46 71.
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin
59:46 72.
Administration of UCM765(MT2 agonist) at a dose of 40 mg/kg promotes sleep, whereas a lower dose (10 mg/kg) reduces anxiety. These similar pharmacological effects occurring after the activation of the GABAergic and the MLT systems are likely due to the mu
59:47 73.
The effect of melatonin on glutamate- and its subtype agonists- induced ion currents in rat hippocampal CA1 neurons.
59:48 74.
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
59:48 75.
Outline
59:48 76.
各自的斷崖/ 守護的意義
59:48 77.
Lateral Habenula
59:49 78.
Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
59:49 79.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
59:50 80.
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
59:50 81.
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
59:51 82.
Hypothesis: Hippocampus is a critical structure for the generation of joy and happiness. *5
59:51 83.
Chronic agomelatine treatment completely prevented the stress-induced increase of glutamate release in the rat prefrontal and frontal cortex.
59:51 84.
The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders
59:52 85.
Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.
59:52 86.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
59:52 87.
Towards a glutamate hypothesis of depression *1
59:53 88.
③ 7 days
59:53 89.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
59:54 90.
Agomelatine: effects on self-referential processing in the amygdala
59:54 91.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
59:54 92.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
59:55 93.
Outline
59:55 94.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
1:01:26 95.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
1:01:26 96.
Agomelatine: effects on self-referential processing in the amygdala
1:01:27 97.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
1:01:29 98.
Agomelatine: effects on self-referential processing in the amygdala
1:01:29 99.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.

分享
- 嵌入網址
- QR code

索引
筆記
討論
全螢幕

1081117 Agomelatine, anhedonia and underlying mechanisms(決定版）

長度: 1:06:13, 瀏覽: 1003, 最近修訂: 2019-11-17

00:00 1.
Agomelatine, Anhedonia and Underlying Mechanism
00:05 2.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
00:06 3.
Positive mental health outcomes (eg, well-being) Biology of positive psychiatry constructs
00:07 4.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
00:09 5.
Agomelatine, Anhedonia and Underlying Mechanism
01:18 6.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
01:18 7.
Agomelatine, Anhedonia and Underlying Mechanism
02:09 8.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
02:24 9.
Agomelatine, Anhedonia and Underlying Mechanism
05:08 10.
The science of psychology has been far more successful on the negative than on the positive side⋯little about his potentialities, his virtues, his achievable aspirations, or his full psychological height. — A.H. Ma
06:02 11.
Positive mental health outcomes (eg, well-being) Biology of positive psychiatry constructs
07:50 12.
Part I. Positive mental health outcomes —Agomelatine and anhedonia of MDD Part II. Biology of positive psychiatry constructs
08:10 13.
Aiming for Functional Recovery of MDD:Reasons to consider Agomelatine
10:26 14.
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open‐label, real‐world study
11:22 15.
Prevalence: apathy/ indifference/ low motivation— 20-40%Delayed or insidious onset Completely resolvable with a dose-lowering and/or discontinuation of the SSRI *180% of patients with SSRI-induced sexual dysfunction also describe clinically significant bl
12:27 16.
An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness.
13:06 17.
persistence of psychosocial dysfunction despite a symptomatic response to antidepressant treatment
13:43 18.
Slide 10
14:32 19.
Outline
15:01 20.
Building a neuroscience of pleasure and well-being (Happiness) *1
18:34 21.
PFC-Limbic-Midbrain
20:07 22.
Activating positive memory engrams suppresses depression-like behavior and anhedonia *1
21:46 23.
Outline
22:04 24.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:23 25.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
23:25 26.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:26 27.
Outline
23:31 28.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
23:32 29.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
24:29 30.
Agomelatine: effects on self-referential processing in the amygdala
24:45 31.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
27:48 32.
③ 7 days
27:48 33.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
28:03 34.
③ 7 days
29:01 35.
Towards a glutamate hypothesis of depression *1
32:11 36.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
32:12 37.
Towards a glutamate hypothesis of depression *1
32:32 38.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
32:54 39.
Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.
33:32 40.
The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders
36:30 41.
Chronic agomelatine treatment completely prevented the stress-induced increase of glutamate release in the rat prefrontal and frontal cortex.
37:46 42.
Hypothesis: Hippocampus is a critical structure for the generation of joy and happiness. *5
41:02 43.
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
42:52 44.
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
44:11 45.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
44:54 46.
Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
46:56 47.
Lateral Habenula
49:18 48.
各自的斷崖/ 守護的意義
51:37 49.
Outline
51:42 50.
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
52:27 51.
The effect of melatonin on glutamate- and its subtype agonists- induced ion currents in rat hippocampal CA1 neurons.
52:35 52.
Administration of UCM765(MT2 agonist) at a dose of 40 mg/kg promotes sleep, whereas a lower dose (10 mg/kg) reduces anxiety. These similar pharmacological effects occurring after the activation of the GABAergic and the MLT systems are likely due to the mu
52:48 53.
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin
53:43 54.
Melatonin in Antinociception: Its Therapeutic Applications
54:16 55.
Outline
54:19 56.
Hippocampal Substructural Vulnerability to Sleep Disturbance and Cognitive Impairment in Patients with Chronic Primary Insomnia: Magnetic Resonance Imaging Morphometry
55:12 57.
The Role of Sleep in Emotional Brain Function
55:44 58.
Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings
55:57 59.
Agomelatine increases and regulates slow-wave sleep.
56:19 60.
Conclusions(1)
57:25 61.
Conclusions(2)
58:06 62.
Slide 46
59:43 63.
Conclusions(2)
59:44 64.
Conclusions(1)
59:44 65.
Agomelatine increases and regulates slow-wave sleep.
59:45 66.
Is Chronic Insomnia a Precursor to Major Depression? Epidemiological and Biological Findings
59:45 67.
The Role of Sleep in Emotional Brain Function
59:45 68.
Hippocampal Substructural Vulnerability to Sleep Disturbance and Cognitive Impairment in Patients with Chronic Primary Insomnia: Magnetic Resonance Imaging Morphometry
59:45 69.
Outline
59:46 70.
Melatonin in Antinociception: Its Therapeutic Applications
59:46 71.
Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin
59:46 72.
Administration of UCM765(MT2 agonist) at a dose of 40 mg/kg promotes sleep, whereas a lower dose (10 mg/kg) reduces anxiety. These similar pharmacological effects occurring after the activation of the GABAergic and the MLT systems are likely due to the mu
59:47 73.
The effect of melatonin on glutamate- and its subtype agonists- induced ion currents in rat hippocampal CA1 neurons.
59:48 74.
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
59:48 75.
Outline
59:48 76.
各自的斷崖/ 守護的意義
59:48 77.
Lateral Habenula
59:49 78.
Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
59:49 79.
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.
59:50 80.
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
59:50 81.
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
59:51 82.
Hypothesis: Hippocampus is a critical structure for the generation of joy and happiness. *5
59:51 83.
Chronic agomelatine treatment completely prevented the stress-induced increase of glutamate release in the rat prefrontal and frontal cortex.
59:51 84.
The Effects of Antidepressant Treatment in Prenatally Stressed Rats Support the Glutamatergic Hypothesis of Stress-Related Disorders
59:52 85.
Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala.
59:52 86.
Blockade of stress-induced increase of glutamate release in the rat prefrontal/ frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways
59:52 87.
Towards a glutamate hypothesis of depression *1
59:53 88.
③ 7 days
59:53 89.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
59:54 90.
Agomelatine: effects on self-referential processing in the amygdala
59:54 91.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
59:54 92.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
59:55 93.
Outline
59:55 94.
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
1:01:26 95.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.
1:01:26 96.
Agomelatine: effects on self-referential processing in the amygdala
1:01:27 97.
Reduced Right Ventrolateral Prefrontal Cortex Activity While Inhibiting Positive Affect is Associated with Improvement in Hedonic Capacity after 8 Weeks of Antidepressant Treatment in Major Depressive Disorder
1:01:29 98.
Agomelatine: effects on self-referential processing in the amygdala
1:01:29 99.
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine and serotonin systems in the rat brain.

位置

資料夾名稱

保健中心

發表人

江堤莊

單位

台大醫學院資訊組

建立

2019-11-17 17:19:36

最近修訂

2019-11-17 18:26:40

長度

1:06:13